Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HK1 | P19367 | 4/20 | 0.37 |
| ▸ | HK2 | P52789 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137969 | 0.88 | CYP3A4 (0.50) | BTN3A1CYP3A4CYP2C9HK1HK2 | |
| SCHEMBL25836522 | 0.86 | BTN3A1 (0.44) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL25835203 | 0.84 | AMDHD2 (0.36) | — | |
| SCHEMBL21137951 | 0.78 | CYP3A4 (0.40) | BTN3A1CYP3A4CYP2C9HK1HK2 | |
| SCHEMBL21058349 | 0.78 | HK1 (0.44) | HK1HK2 | |
| SCHEMBL21138301 | 0.74 | NT5E (0.40) | HK1HK2 | |
| SCHEMBL21137950 | 0.73 | AMDHD2 (0.44) | HK1HK2 | |
| SCHEMBL21058377 | 0.72 | PYGB (0.40) | HK1HK2 | |
| SCHEMBL28855900 | 0.72 | HK1 (0.46) | HK1HK2 | |
| SCHEMBL19236210 | 0.72 | BTN3A1 (0.64) | BTN3A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | BTN3A1 3409/4885CYP3A4 3581/4885CYP2C9 1912/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | BTN3A1 3409/4885CYP3A4 3581/4885CYP2C9 1912/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | BTN3A1 4175/4885CYP3A4 1515/4885CYP2C9 591/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | BTN3A1 4175/4885CYP3A4 1515/4885CYP2C9 591/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | BTN3A1 4175/4885CYP3A4 1515/4885CYP2C9 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.